Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes

American Journal of Pathology

Volumn 166, Issue 2, 2005, Pages 557-563

  Campioni, Diana ^a   Secchiero, Paola ^a   Corallini, Federica ^a   Melloni, Elisabetta ^a   Capitani, Silvano ^a   Lanza, Francesco ^a   Zauli, Giorgio ^b  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPHORIN A; HEMOGLOBIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADULT; AGED; ARTICLE; BONE MARROW CELL; CELL MATURATION; CLINICAL FEATURE; CONTROLLED STUDY; ERYTHROBLAST; ERYTHROPOIESIS; FEMALE; HUMAN; IMMUNOCYTOCHEMISTRY; MALE; MYELODYSPLASTIC SYNDROME; MYELOID PROGENITOR CELL; PRIORITY JOURNAL;

EID: 13244290233     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)62277-8     Document Type: Article

References (30)

1. Heaney ML, Golde DW: Myelodysplasia. N Engl J Med 1999, 340:1649-1660
2. Bennett JM: World Health Organization classification of the 399 acute leukemias and myelodysplastic syndrome. Int J Hematol 2002, 72:131-133
3. Raza A, Gezer S, Mundle S, Gao XZ, Alvi S, Borok R, Rifkin S, Iftikhar A, Shetty V, Parcharidou A: Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 1995, 86:268-276
4. Bogdanovic AD, Jankovic GM, Colovic MD, Trpinac DP, Bumbasirevic VZ: Apoptosis in bone marrow of myelodysplastic syndrome patients. Blood 1996, 87:3064-3066
5. Mundle S, Venugopal P, Shetty V, Ali A, Chopra H, Handa H, Rose S, Mativi BY, Gregory SA, Preisler HD, Raza A: The relative extent and propensity of CD34+ vs. CD34- cells to undergo apoptosis in myelodysplastic marrows. Int J Hematol 1999, 69:152-159
6. Parker EJ, Mufti GJ, Rasool F, Mijovic A, Devereux S, Pagliuca A: The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood 2000, 96:3932-3938
7. Novitzky N, Mohamed R, Finlayson J, du Toit C: Increased apoptosis of bone marrow cells and preserved proliferative capacity of selected progenitors predict for clinical response to anti-inflammatory therapy in myelodysplastic syndromes. Exp Hematol 2000, 28:941-949
8. Shetty V, Hussaini S, Broady-Robinson L, Allampallam K, Mundle S, Borok R, Broderick E, Mazzoran L, Zorat F, Raza A: Intramedullary apoptosis of hemopoietic cells in myelodysplastic syndrome patients can be massive: apoptotic cells recovered from high-density fraction of bone marrow aspirates. Blood 2000, 96:1388-1392
9. Bouscary D, De Vos J, Guesnu M, Jondeau K, Viguier F, Melle J, Picard F, Dreyfus F, Fontenay-Roupie M: Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes. Leukemia 1997, 11:839-845
10. Gersuk GM, Beckham C, Loken MR, Kiener P, Anderson JE, Farrand A, Troutt AB, Ledbetter JA, Deeg HJ: A role for tumor necrosis factor-α, Fas, and Fas-ligand in marrow failure associated with myelodysplastic syndrome. Br J Haematol 1998, 103:176-188
11. Deeg HJ, Beckham C, Loken MR, Bryant E, Lesnikova M, Shulman HM, Gooley T: Negative regulators of hemopoiesis and stroma function in patients with myelodysplastic syndrome. Leuk Lymphoma 2000, 37:405-414
12. Allampallam K, Shetty V, Mundle S, Dutt D, Kravitz H, Reddy PL, Alvi S, Galili N, Saberwal GS, Anthwal S, Shaikh MW, York A, Raza A: Biological significance of proliferation, apoptosis, cytokines, and monocyte/macrophage cells in bone marrow biopsies of 145 patients with myelodysplastic syndrome. Int J Hematol 2002, 75:289-297
13. Maciejewski JP, Risitano A, Sloand EM, Wisch L, Geller N, Barrett JA, Young NS, Ristiano AM: A pilot study of the recombinant soluble human tumour necrosis factor receptor (p75)-Fc fusion protein in patients with myelodysplastic syndrome. Br J Haematol 2002, 117:119-126
14. Claessens YE, Bouscary D, Dupont JM, Picard F, Melle J, Gisselbrecht S, Lacombe C, Dreyfus F, Mayeux P, Fontenay-Roupie M: In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis. Blood 2002, 99:1594-1601
15. Tauro S, Hepburn MD, Peddie CM, Bowen DT, Pippard MJ: Functional disturbance of marrow stromal microenvironment in the myelodysplastic syndromes. Leukemia 2002, 16:785-790
16. Deeg HJ: Marrow stroma in MDS: culprit or bystander? Leuk Res 2002, 26:687-688
17. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995, 3:673-682
18. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A: Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996, 271:12687-12690
19. Ehrlich S, Infante-Duarte C, Seeger B, Zipp F: Regulation of soluble and surface-bound TRAIL in human T cells, B cells, and monocytes. Cytokines 2003, 24:244-253
20. LeBlanc HN, Ashkenazi A: Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 2003, 10:66-75
21. Zang DY, Goodwin RG, Loken MR, Bryant E, Deeg HJ: Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myeiodysplastic syndrome: effects on in vitro hemopoiesis. Blood 2001, 98:3058-3065
22. Plasilova M, Zivny J, Jelinek J, Neuwirtova R, Cermak J, Necas E, Andera L, Stopka T: TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors. Leukemia 2002, 16:67-73
23. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC, Lynch DH: Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999, 5:157-16
24. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z, Schwall RH: Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999, 104:155-162
25. De Maria R, Zeuner A, Eramo A, Domenichelli C, Bonci D, Grignani F, Srinivasuia SM, Alnemri ES, Testa U, Peschie C: Negative regulation of erythropoiesis by caspase-mediated cleavage of GATA-1. Nature 1999, 401:489-493
26. Zamai L, Secchiero P, Pierpaoli S, Bassini A, Papa S, Alnemri ES, Guidotti L, Vitale M, Zauli G: TNF-related apoptosis-inducing ligand (TRAIL) as a negative regulator of normal human erythropoiesis. Blood 2000, 95:3716-3724
27. Secchiero P, Melloni E, Heikinheimo M, Mannisto S, Di Pietro R, lacone A, Zauli G: TRAIL regulates normal erythroid maturation through an ERK-dependent pathway. Blood 2004, 103:517-522
28. Schmidt U, van den Akker E, Parren-van Amelsvoort M, Litos G, De Bruijn M, Gutierrez L, Hendriks RW, Ellmeier W, Lowenberg B, Beug H, Von Lindern M: Btk is required for an efficient response to erythropoietin and for SCF-controlled protection against TRAIL in erythroid cells. J Exp Med 2004, 199:785-795
29. Lanza F, Campioni D, Moretti S, Dominici M, Punturieri M, Focarile E, Pauli S, Dabusti M, Tieghi A, Bacilieri M, Scapoli C, De Angeli C, Galluccio L, Castoldi G: CD34+ cell subsets and long-term culture colony-forming cells (LTC-CFC) evaluated on both autologous and normal bone marrow stroma predict long-term hematopoietic engraftment in patients receiving autologous peripheral blood stem cell transplantation. Exp Hematol 2001, 29:1484-1493
30. Chen G, Zeng W, Miyazato A, Billings E, Maciejewski JP, Kajïgaya S, Sloand EM, Young NS: Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities. Blood First Edition; DOI 10.1182/blood-2004-01-0103